The modulation of macrophage subsets in celiac disease pathogenesis.
autoimmune disease
celiac disease
gluten
inflammation
intestinal disease
macrophages
tissue homeostasis
Journal
Immunity, inflammation and disease
ISSN: 2050-4527
Titre abrégé: Immun Inflamm Dis
Pays: England
ID NLM: 101635460
Informations de publication
Date de publication:
12 2022
12 2022
Historique:
revised:
12
10
2022
received:
02
08
2022
accepted:
06
11
2022
entrez:
29
11
2022
pubmed:
30
11
2022
medline:
1
12
2022
Statut:
ppublish
Résumé
So far, limited studies have focused on the role of Macrophages (MQs) in the development or progression of celiac disease (CD). Researchers believe that increasing knowledge about the function of MQs in inflammatory disorders plays a critical role in finding a new treatment for these kinds of diseases. CD is a permanent autoimmune intestinal disorder triggered by gluten exposure in predisposed individuals. This disorder happens due to the loss of intestinal epithelial barrier integrity characterized by dysregulated innate and adaptive immune responses. MQs are known as key players of the innate immune system that link innate and adaptive immunity. MQs of human intestinal lamina propria participate in maintaining tissue homeostasis, and also intestinal inflammation development. Previous studies suggested that gliadin triggers a proinflammatory phenotype (M1 MQ) in human primary MQs. Moreover, M2-related immunosuppressive mediators are also present in CD. In fact, CD patients present an impaired transition from pro-inflammatory to anti-inflammatory responses due to inappropriate responses to gliadin peptides. The M1/M2 MQs polarization balancing regulators can be considered novel therapeutic targets for celiac disease.
Sections du résumé
BACKGROUND
So far, limited studies have focused on the role of Macrophages (MQs) in the development or progression of celiac disease (CD). Researchers believe that increasing knowledge about the function of MQs in inflammatory disorders plays a critical role in finding a new treatment for these kinds of diseases.
MAIN BODY
CD is a permanent autoimmune intestinal disorder triggered by gluten exposure in predisposed individuals. This disorder happens due to the loss of intestinal epithelial barrier integrity characterized by dysregulated innate and adaptive immune responses. MQs are known as key players of the innate immune system that link innate and adaptive immunity. MQs of human intestinal lamina propria participate in maintaining tissue homeostasis, and also intestinal inflammation development. Previous studies suggested that gliadin triggers a proinflammatory phenotype (M1 MQ) in human primary MQs. Moreover, M2-related immunosuppressive mediators are also present in CD. In fact, CD patients present an impaired transition from pro-inflammatory to anti-inflammatory responses due to inappropriate responses to gliadin peptides.
CONCLUSION
The M1/M2 MQs polarization balancing regulators can be considered novel therapeutic targets for celiac disease.
Identifiants
pubmed: 36444633
doi: 10.1002/iid3.741
pmc: PMC9667199
doi:
Substances chimiques
Gliadin
9007-90-3
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e741Informations de copyright
© 2022 The Authors. Immunity, Inflammation and Disease published by John Wiley & Sons Ltd.
Références
Hum Immunol. 2010 Jan;71(1):50-7
pubmed: 19735687
Pediatr Rheumatol Online J. 2016 Dec 9;14(1):66
pubmed: 27938384
Gastroenterol Hepatol Bed Bench. 2021 Winter;14(1):36-43
pubmed: 33868608
United European Gastroenterol J. 2019 Jun;7(5):583-613
pubmed: 31210940
Immune Netw. 2022 Jun 13;22(4):e33
pubmed: 36081527
PLoS One. 2019 Apr 18;14(4):e0215132
pubmed: 30998704
Mucosal Immunol. 2022 Jan;15(1):74-83
pubmed: 34420044
Biomedicines. 2022 Apr 09;10(4):
pubmed: 35453624
Sci Rep. 2020 Mar 2;10(1):3791
pubmed: 32123188
Pflugers Arch. 2017 Apr;469(3-4):527-539
pubmed: 28283748
Lab Invest. 2005 Mar;85(3):397-407
pubmed: 15608660
Biomedicines. 2018 Sep 09;6(3):
pubmed: 30205595
Nat Immunol. 2013 Oct;14(10):986-95
pubmed: 24048120
J Med Microbiol. 2007 Dec;56(Pt 12):1669-1674
pubmed: 18033837
Front Immunol. 2021 Sep 28;12:749708
pubmed: 34650568
Exp Ther Med. 2017 Jul;14(1):3-9
pubmed: 28672886
J Neurogastroenterol Motil. 2019 Jul 1;25(3):363-376
pubmed: 31327219
BMC Cancer. 2015 Aug 08;15:577
pubmed: 26253167
J Pharmacol Exp Ther. 2017 Mar;360(3):435-444
pubmed: 28057839
Gastroenterology. 2020 May;158(6):1667-1681.e12
pubmed: 32032584
J Cardiovasc Pharmacol. 2014 Jun;63(6):544-52
pubmed: 24709638
Front Immunol. 2021 Mar 08;12:620510
pubmed: 33763066
J Clin Immunol. 2007 Mar;27(2):201-9
pubmed: 17260166
Nat Rev Immunol. 2014 Aug;14(8):571-8
pubmed: 25033907
J Nutr Biochem. 2018 Apr;54:11-17
pubmed: 29216605
Int J Mol Sci. 2019 Nov 09;20(22):
pubmed: 31717494
Zhongguo Zhong Yao Za Zhi. 2020 May;45(9):2158-2164
pubmed: 32495566
Front Pediatr. 2018 Nov 21;6:350
pubmed: 30519552
Sci Rep. 2020 Jul 1;10(1):10798
pubmed: 32612145
Phytochem Rev. 2018 Feb;17(1):1-16
pubmed: 29651231
J Pediatr Gastroenterol Nutr. 2014 Jul;59 Suppl 1:S7-9
pubmed: 24979197
Biochem Biophys Res Commun. 2022 Apr 16;600:35-43
pubmed: 35182973
J Immunol. 2006 Feb 15;176(4):2512-21
pubmed: 16456012
Front Immunol. 2021 Feb 12;12:574425
pubmed: 33643308
J Hum Nutr Diet. 2007 Oct;20(5):423-30
pubmed: 17845376
J Cell Physiol. 2018 Sep;233(9):6425-6440
pubmed: 29319160
BMC Gastroenterol. 2020 Aug 6;20(1):258
pubmed: 32762724
J Microbiol Immunol Infect. 2021 Aug;54(4):673-679
pubmed: 32299786
J Immunol. 2019 Aug 1;203(3):593-599
pubmed: 31332080
J Clin Invest. 1977 May;59(5):966-74
pubmed: 323291
Cell Mol Gastroenterol Hepatol. 2021;12(5):1701-1718
pubmed: 34506953
N Engl J Med. 2007 Oct 25;357(17):1731-43
pubmed: 17960014
Sci Rep. 2021 Jan 27;11(1):2383
pubmed: 33504878
Front Immunol. 2019 May 24;10:1140
pubmed: 31178867
Front Immunol. 2017 Feb 09;8:120
pubmed: 28232836
Front Immunol. 2019 Apr 17;10:799
pubmed: 31057539
Front Nutr. 2019 Nov 05;6:167
pubmed: 31750310
Front Immunol. 2019 Aug 07;10:1895
pubmed: 31440258
Probiotics Antimicrob Proteins. 2020 Sep;12(3):798-808
pubmed: 31741313
Immunol Rev. 2014 Jul;260(1):221-34
pubmed: 24942692
Biochem Pharmacol. 2006 Jun 28;72(1):62-9
pubmed: 16678799
Science. 2002 Sep 27;297(5590):2275-9
pubmed: 12351792
Blood. 2002 May 1;99(9):3427-31
pubmed: 11964313
Oncotarget. 2018 Apr 3;9(25):17937-17950
pubmed: 29707159
Nat Immunol. 2010 Oct;11(10):889-96
pubmed: 20856220
Appl Clin Genet. 2021 Feb 11;14:37-50
pubmed: 33603437
Blood. 2004 Nov 15;104(10):3021-7
pubmed: 15284119
Front Immunol. 2014 Oct 17;5:514
pubmed: 25368618
Clin Dermatol. 2007 Jan-Feb;25(1):9-18
pubmed: 17276196
Dig Dis Sci. 2013 Nov;58(11):3242-5
pubmed: 23812827
Int J Mol Sci. 2017 Dec 29;19(1):
pubmed: 29286292
Cell Physiol Biochem. 2015;36(2):631-41
pubmed: 25998190
PLoS One. 2013 Apr 29;8(4):e62426
pubmed: 23658628
Immunology. 2011 Mar;132(3):432-40
pubmed: 21091908